US pauses distribution of Lilly mAb combo to Massachusetts due to Covid-19 variant
Now that the CDC has found that the Covid-19 variant originally identified in Brazil is circulating with a frequency exceeding 10% in Massachusetts, the US has halted shipments of Eli Lilly’s monoclonal antibody combo treatment because it’s not active against this variant.
The FDA recommends that health care providers in Massachusetts use Regeneron’s monoclonal antibody as an alternative to Lilly’s therapy until further notice.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.